Amgen's (AMGN) CodeBreak200 Has Some Risk From Docetaxel - Jefferies

June 15, 2022 9:16 AM EDT Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $295.00 price target on Amgen (NASDAQ: AMGN) on the belief that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login